Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Konstantinos Arnaoutakis

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address10-54 Cancer Institute
4104 Outpatient Circle
Mail Slot # 508
Little Rock AR 72205
Phone501-526-6990 x8064
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Konstantinos Arnaoutakis is a hematologist and oncologist at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. He is also an Associate Professor in the Department of Internal Medicine, Division of Hematology and Oncology. Dr. Arnaoutakis received his medical degree from the University of Patras Medical School in Greece. He served an internal medicine residency at Albany Medical College-Albany Medical Center Hospital. He also served a fellowship in hematology and oncology at Tufts University, St. Elizabeth's Medical Center in Boston, MA. He later went on to serve as Chief Hematology and Medical Oncology Fellow at Tufts University. He is board certified in internal medicine, hematology and oncology. He is a member of the American Medical Association, American College of Physician, American Society of Clinical Oncology and American Society of Hematology. His primary research interests are lung cancer, head and neck cancer and genitourinary cancers.


    Collapse Research 
    Collapse research activities and funding
    S1900B     (ARNAOUTAKIS, KONSTANTINOS)Jun 26, 2020
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1900B: A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study) (260759)
    Role: Principal Investigator

    S1900C     (ARNAOUTAKIS, KONSTANTINOS)May 18, 2020
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) (260760)
    Role: Principal Investigator

    S1400F     (ARNAOUTAKIS, KONSTANTINOS)Aug 20, 2019
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1400F: A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study) (IRB 239474)
    Role: Principal Investigator

    S1800A     (ARNAOUTAKIS, KONSTANTINOS)Jul 3, 2019
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (IRB 239473)
    Role: Principal Investigator

    S1900A     (ARNAOUTAKIS, KONSTANTINOS)Jul 3, 2019
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1900A - A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) (IRB 239475)
    Role: Principal Investigator

    CA209817     (ARNAOUTAKIS, KONSTANTINOS)Sep 13, 2018
    Bristol-Meyers Squibb
    A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer (CheckMate 817, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation)
    Role: Principal Investigator

    2015-001241-84     (ARNAOUTAKIS, KONSTANTINOS)May 22, 2017 - Jun 1, 2020
    NOVARTIS Pharmaceuticals Corporation
    A phase Ib/II, open-label, multictr trial w/ oral cMET inhibitor INC280 alone & combined with erlotinib vs platinum/pemetrexed in adult patients w/ EGFR mutated, cMET-amplified, locally advanced/metastatic NSCLC with acquired resistance to prior EGFR TKI
    Role: Principal Investigator

    HHSF223201610111C     (JOHANN JR, DONALD)Oct 1, 2016 - Sep 29, 2020
    U.S. Food and Drug Administration - Pass Through: Arkansas Research Alliance
    Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine
    Role: Co-Investigator

    GO29527     (ARNAOUTAKIS, KONSTANTINOS)Aug 1, 2016
    Genentech, Inc.
    A Phase 3, MPDL3280A versus BSC Following Adjuvant Cisplain-Based Chemo in PD-L1-Selected Pts w Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer 204344
    Role: Principal Investigator

    GO29437     (ARNAOUTAKIS, KONSTANTINOS)Jun 29, 2016
    Genentech, Inc.
    PHASE 3 Study EVAL EFFICACY AND SAFETY OF MPDL32 80A (IN COMBINATION W CARBOPLATIN+PACLITAXEL OR MPDL3280A IN COMBO W CARBO+NAB -PACLITAXEL VERSUS CARBO+NAB-PACLITAXEL IN CHEMO-NAÏVE PTS W STAGE 4 SQUAMOUS NON SMALL CELL LUNG CANCER
    Role: Principal Investigator

    C4-189368     (ARNAOUTAKIS, KONSTANTINOS)Jun 2, 2016
    Genentech, Inc.
    GO29537
    Role: Principal Investigator

    HHSF223201510172C     (JOHANN JR, DONALD)Sep 30, 2015 - Mar 31, 2019
    U.S. Food and Drug Administration - Pass Through: Arkansas Research Alliance
    Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine
    Role: Co-Investigator

    VRPX-A202     (ARNAOUTAKIS, KONSTANTINOS)Jul 16, 2014
    VentiRx Pharmaceuticals
    VRPX-A202
    Role: Principal Investigator

    AGS-003-007     (ARNAOUTAKIS, KONSTANTINOS)Sep 10, 2013
    Argos Therapeutics, Inc
    An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS 003) Plus Standard Treatment of Advanced Renal Cell Carcinom
    Role: Principal Investigator

    ABT-888     (ARNAOUTAKIS, KONSTANTINOS)Aug 23, 2013
    AbbVie Inc
    A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy versus Plac
    Role: Principal Investigator

    Afatinib 1200.43     (ARNAOUTAKIS, KONSTANTINOS)Nov 29, 2012
    Boehringer Ingleheim Pharmaceuticals, Inc.
    A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients
    Role: Principal Investigator

    BP1200.43     (ARNAOUTAKIS, KONSTANTINOS)Oct 23, 2012
    Boehringer Ingleheim Bioproducts
    A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients
    Role: Principal Investigator

    IMA901     (ARNAOUTAKIS, KONSTANTINOS)Apr 12, 2012 - Jul 31, 2014
    Immatics Biotechnologies
    A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients receiving Sunitinib as First-Line Therapy for Ad
    Role: Principal Investigator

    PAZ113758     (ARNAOUTAKIS, KONSTANTINOS)Jan 15, 2012 - Aug 10, 2015
    GlaxoSmithKline
    A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects wi
    Role: Principal Investigator

    PF-00299804     (ARNAOUTAKIS, KONSTANTINOS)Nov 22, 2011
    Pfizer, Inc.
    Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C
    Role: Principal Investigator

    IRESSA     (ARNAOUTAKIS, KONSTANTINOS)Sep 16, 2011
    AstraZeneca
    An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™) for the continued treatment of patients in the United State
    Role: Principal Investigator

    A4021032 Phase 2     (ARNAOUTAKIS, KONSTANTINOS)Sep 9, 2010
    Pfizer, Inc.
    A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a
    Role: Principal Investigator

    A8081005 Phase 2 EML4-ALK     (ARNAOUTAKIS, KONSTANTINOS)Feb 15, 2010
    Pfizer, Inc.
    Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Echino
    Role: Principal Investigator

    A8081007 Phase 3 NSCLC     (ARNAOUTAKIS, KONSTANTINOS)Jan 27, 2010 - Jan 1, 2015
    Pfizer, Inc.
    Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Abdallah AO, Coleman H, Kamel M, Davis R, Landrum T, Spencer H, Mackintosh S, Mahmoud FA, Milojkovic N, Wicker C, Arnaoutakis K, Nakagawa M. A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant. SAGE Open Med. 2018; 6:2050312118800202. PMID: 30245818.
      View in: PubMed
    2. Apopa PL, Alley L, Penney RB, Arnaoutakis K, Steliga MA, Jeffus S, Bircan E, Gopalan B, Jin J, Patumcharoenpol P, Jenjaroenpun P, Wongsurawat T, Shah N, Boysen G, Ussery D, Nookaew I, Fagan P, Bebek G, Orloff MS. PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin. Front Microbiol. 2018; 9:1757. PMID: 30127774.
      View in: PubMed
    3. Sherman AC, Simonton-Atchley S, Mikeal CW, Anderson KM, Arnaoutakis K, Hutchins LF, Makhoul I, Mahmoud F, Milojkovic N, Harrington SE, Suen JY. Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study. J Psychosoc Oncol. 2018 Jul-Aug; 36(4):454-469. PMID: 29863447.
      View in: PubMed
    4. Johann DJ, Steliga M, Shin IJ, Yoon D, Arnaoutakis K, Hutchins L, Liu M, Liem J, Walker K, Pereira A, Yang M, Jeffus SK, Peterson E, Xu J. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp Biol Med (Maywood). 2018 02; 243(3):262-271. PMID: 29405770.
      View in: PubMed
    5. Makhoul I, Motwani P, Schafer L, Arnaoutakis K, Mahmoud F, Safar M, Graves D, Mehta P, Govindarajan R, Hutchins L, Thrush C. Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program. J Cancer Educ. 2018 02; 33(1):186-192. PMID: 27516202.
      View in: PubMed
    6. Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV. Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 1. PMID: 31032471.
      View in: PubMed
    7. Nima ZA, Alwbari AM, Dantuluri V, Hamzah RN, Sra N, Motwani P, Arnaoutakis K, Levy RA, Bohliqa AF, Nedosekin D, Zharov VP, Makhoul I, Biris AS. Targeting nano drug delivery to cancer cells using tunable, multi-layer, silver-decorated gold nanorods. J Appl Toxicol. 2017 Dec; 37(12):1370-1378. PMID: 28730725.
      View in: PubMed
    8. Jeffus SK, Gardner JM, Steliga MA, Shah AA, Stelow EB, Arnaoutakis K. Hyalinizing Clear Cell Carcinoma of the Lung: Case Report and Review of the Literature. Am J Clin Pathol. 2017 Jul 01; 148(1):73-80. PMID: 28927164.
      View in: PubMed
    9. Bansal M, Abdallah AO, Pennisi A, Arnaoutakis K, Makhoul I, Mehta P. Improving Communication on Intent of Chemotherapy Using QOPI Scores and PDSA Cycles. J Cancer Educ. 2016 12; 31(4):736-741. PMID: 26411307.
      View in: PubMed
    10. Kaur V, Haider S, Sasapu A, Mehta P, Arnaoutakis K, Makhoul I. Addressing Opioid-Associated Constipation Using Quality Oncology Practice Initiative Scores and Plan-Do-Study-Act Cycles. J Oncol Pract. 2017 01; 13(1):e91-e97. PMID: 28084881.
      View in: PubMed
    11. Mahmoud F, Abdallah AO, Arnaoutakis K, Makhoul I. Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. Perm J. 2016; 20(3):15-149. PMID: 27352410.
      View in: PubMed
    12. Ravilla R, Joiner AK, Alapat D, Arnaoutakis K. An Unusual Case of Acute Promyelocytic Leukemia Presenting With Hypoplastic Bone Marrow and Pancytopenia. Am J Med Sci. 2016 Mar; 351(3):317-8. PMID: 26992265.
      View in: PubMed
    13. Arnaoutakis K, Anders M, Berry K. Simulating Four Essential Conversations with Hematology/Oncology Trainees: a Qualitative Evaluation. J Cancer Educ. 2016 Mar; 31(1):55-62. PMID: 25926020.
      View in: PubMed
    14. Pai VB, Ravilla R, Lindberg M, Steliga M, Arnaoutakis K. Myxoid mesenchymal neoplasm presenting as massive arm and chest wall oedema with pleural effusion. Ecancermedicalscience. 2015; 9:590. PMID: 26635894.
      View in: PubMed
    15. Gokden M, Ariza A, Arnaoutakis K. Molecular Markers in the Diagnosis and Treatment of Cancer. Biomed Res Int. 2015; 2015:105217. PMID: 26451364.
      View in: PubMed
    16. Arnaoutakis K. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015 02 12; 372(7):683. PMID: 25671265.
      View in: PubMed
    17. Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4. PMID: 25042026.
      View in: PubMed
    18. Robertson WW, Steliga MA, Siegel ER, Arnaoutakis K. Accuracy of fine needle aspiration and core lung biopsies to predict histology in patients with non-small cell lung cancer. Med Oncol. 2014 Jun; 31(6):967. PMID: 24777549.
      View in: PubMed
    19. Dholaria B, Alapat D, Arnaoutakis K. Primary bone marrow Hodgkin lymphoma in an HIV-negative patient. Int J Hematol. 2014 Apr; 99(4):503-7. PMID: 24532438.
      View in: PubMed
    20. Khetpal R, Katz MD, Cox M, Arnaoutakis K. The role of salvage hemiscrotectomy in testicular cancer after scrotal contamination: a case report and literature review. Clin Genitourin Cancer. 2014 Jun; 12(3):e103-5. PMID: 24461625.
      View in: PubMed
    21. Rao A, Griffiths R, Arnaoutakis K. Paralyzed by a rare cause: an unusual case of metastatic diffuse large B cell lymphoma of the intramedullary spinal cord. Ann Hematol. 2014 Feb; 93(2):337-8. PMID: 23712293.
      View in: PubMed
    22. Arnaoutakis K, Graves DA, Hutchins LF, Kieber-Emmons TK. Melanoma - From Early Detection to Treatment. Immunomodulation. 2013.
    23. Khetpal R, Arnaoutakis K, Dholaria B. CMV esophagitis-sequelae of radiation therapy. Esophagus. 2013; 10:244-246.
    24. Pandey S, Bellamy W, Arnaoutakis K, Singh ZN. Gains of 2p23/ALK locus are common in non-small cell lung carcinoma: Clinical and molecular correlations. 2012.
    25. Robertson WW, Steliga M, Arnaoutakis K. Accuracy of fine needle aspiration and core lung biopsies to predict histology in patients with non-small cell lung cancer. 2012.
    26. Arnaoutakis K, Ralph Buschbacher (ed). Geriatrics: Rehabilitation Medicine Quick Reference. Anemia. 2012.
    27. Blanchard EM, Arnaoutakis K, Hesketh PJ. Lung cancer in octogenarians. J Thorac Oncol. 2010 Jun; 5(6):909-16. PMID: 20521358.
      View in: PubMed
    28. Arnaoutakis K, Oo TH. Bronchus-associated lymphoid tissue lymphomas. South Med J. 2009 Dec; 102(12):1229-33. PMID: 20016430.
      View in: PubMed
    29. Arnaoutakis K, Morse, A.B., Ambika, S., Wong G., Parameswaran, R. Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC). 2009.
    30. Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer. 2009 Aug; 17(8):1065-70. PMID: 19066985.
      View in: PubMed
    31. Arnaoutakis K. ASCO's Career Resource Guide Helps Fellows Achieve Success. ASCO News & Forum. 2008.
    32. Arnaoutakis K, Wong G, Parameswaran J. Use of a standardized web-based tool for evaluation of aromatase inhibitor related bone loss in breast cancer patients. Meeting. 2008.
    33. Arnaoutakis K. Evaluation of malignant pleural effusion. Albany Medical Review. 2006; 8(2).
    34. Arnaoutakis K, Mecca, P. A 69-year-old man with abdominal pain and hypotension. Albany Medical Review. 2004; 7(2).
    35. Arnaoutakis K. Recurrent lung melanoma 20 years after previous cutaneous melanoma. Saratoga Upstate Annual Meeting. 2004.
    Arnaoutakis's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description